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Aims The Medtronic EngagerTM aortic valve bioprosthesis is a self-expanding valve with support arms facilitating anatomi-
cally correct positioning and axial fixation. Valve leaflets, made of bovine pericardium, are mounted on a Nitinol
frame. Here, we report the first in man study with this new implant (Trial Identifier NCT00677638).
Methods
and results
Thirty patients (mean age 83.4+ 3.8 years; 83% female) with tricuspid aortic valve stenosis were included in the
study. Mean logistic EuroSCORE was 23.4+ 11.9. Mean aortic annulus diameter was 21.8+1.4 mm. For this
study, the Engager was available in only one size (23 mm), to fit aortic annuli of 19–23 mm. Standard transapical
valve implantation was performed using predilation of the aortic valve and rapid ventricular pacing during ballon val-
vuloplasty and most valve deployments. Accurate valve placement was achieved in 29/30 cases (97%). Post-implant
peak-to-peak gradient was 13.3+ 9.3 mmHg. In 80% of the patients, no more than grade I paravalvular leakage was
observed, in 13% grades I– II and in 3% grade II. Three patients (10%) required permanent pacemaker implantation for
higher-degree or complete atrioventricular block. Four dissections (13%) occurred during positioning of the valve and
were treated surgically in three cases. Thirty-day and in-hospital mortality were 20% and 23%, respectively, and
6-month survival was 56.7%. No structural failure occurred for up to 1 year.
Conclusion This series established the feasibility of implanting a novel self-expanding transapical aortic valve prosthesis predicta-
bly into an anatomically correct position. Observed complications led to complete redesign of the delivery system for
upcoming clinical studies with the goal of establishing safety and performance.
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Introduction
Transcatheter aortic valve implantation is a novel technology,
which is rapidly becoming a routine procedure in many centres
of expertise1,2 even before results from controlled randomized
studies are available. A major reason driving this development is
that despite the excellent results of surgical aortic valve replace-
ment, a substantial proportion of patients, mostly octogenarians
with multiple comorbidities, are not referred for valve replacement
because they are not perceived to be suitable candidates.3,4 In this
patient population, only one-third are expected to be alive by 1
year,5 if left untreated.
In those undergoing transcatheter aortic valve implantation, a
high incidence of paravalvular leaks has been observed, which is
not always well tolerated by the hypertrophied stiff left ventricles
of elderly patients with long-standing aortic stenosis. This, in
addition to challenges in subcoronary device positioning and
annular fixation with existing implants, has led to the development
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of different design concepts for transcatheter valves. Virtually, all
previously reported experience with transapical transcatheter
implantations relates to balloon-expandable prostheses.
The Medtronic Engager (originally Ventor Embracer) is a self-
expanding valve with support arms to allow for anatomical posi-
tioning and axial fixation. Here, we report the first-in-man study
with this new transapical implant.
Methods
Approval by the competent authority as well as the local ethical com-
mittees was obtained for a multi-centre feasibility study of 30 elderly
patients (.75 years of age) with severe (mean gradient .40 mmHg,
aortic valve area ,0.8 cm2) symptomatic aortic stenosis deemed to
be at high risk (logistic EuroSCORE .11%) for surgical aortic valve
replacement. The specific inclusion and exclusion criteria of the
study are listed in Supplementary material online, Appendix. All
patients gave written informed consent. The study was registered
with the NIH at Clinicaltrials.gov (Trial identifier NCT00677638).
The valve
The EngagerTM Aortic Valve Bioprosthesis (Medtronic, Inc., Minneapo-
lis, MN, USA), shown in Figure 1, is a flexible heart valve prosthesis
composed of three leaflets, cut from tissue-fixated bovine pericardium,
sewn to a polyester sleeve, and mounted on a compressible and self-
expanding Nitinol frame (stent assembly). The stent assembly consists
of a main frame and a support frame, which are coupled together so as
to form the commissural posts of the valve. Two types of sewing
materials are used: Polyester and expanded Polytetrafluoroethylene.
The shaped valve prosthesis has a maximal inlet diameter of 28 mm,
a waist diameter of 18 mm, and a diameter at the outlet of 23 mm.
The fluid-dynamic shape is intended to minimize pressure losses at
the inlet and maximize pressure recovery at the outlet. The valve
shape also creates an anatomical fit to facilitate periannular implan-
tation and fixation at the target site with minimal risk of coronary
obstruction (prosthesis confined at the level of the aortic cusps oppo-
site the coronary ostia). Total length of implanted prosthesis is 24 mm
upon deployment, with up to 7 mm seated subannularly (inlet).
For this study, the Engager was available in only one size (labelled as
23 mm according to its diameter at the commissural outlet), which was
designed to fit an aortic annulus size of 19–23 mm.6 The valve is ster-
ilized and stored in a glutaraldehyde solution.
Implant procedure
The study was performed from June 2008 to October 2009 in Leipzig
(26), Cologne (2), and Bad Homburg (2). Except for two implantations,
all procedures were performed in a surgical hybrid suite. All pro-
cedures were performed with the patient prepped and draped as for
full sternotomy and cardiopulmonary bypass in stand-by. Prior to the
procedure, the valve was crimped and mounted on the delivery
system by pulling the valve through a cone-shaped converging tube
using strings. The Engager is mounted onto the delivery catheter at
the shaft’s top connector and the main frame is loaded into the deliv-
ery tube while the support arms and the distal end of the Engager
remain outside.
A standard transapical approach was performed.7 The patient was
placed in a supine position with the left chest slightly elevated. A 6F
femoral arterial sheath was inserted into the right femoral artery and
a pigtail catheter was placed into the aortic root for contrast aortogra-
phy. A 6F introducer sheath was inserted into the right femoral vein
and a guidewire placed in the right atrium to establish access for fast
cannulation in case conversion to extracorporeal circulation became
necessary (safety precaution). Low-dose heparin was given with a
target activated clotting time of 150 s. An incision (5–7 cm) was per-
formed in the fifth or sixth intercostal space for transapical access. An
epicardial temporary pacemaker wire was sutured to the left ventricle
and tested. The pericardium was incised and fixed with stay sutures.
Two apical purse-string sutures with Teflon-felt pledgets were
placed lateral and 2 cm above the true apex with an inner diameter
of approximately 2–3 cm. Rotational angiography for 3D reconstruc-
tion of the aortic root was performed in some cases as previously
described.8 This technique facilitated orthogonal orientation of the
C-arm and improved the ease of anatomically orientating the device.
The left ventricular apex was punctured with an 18 G Seldinger-type
needle. A 14F soft sheath was introduced and positioned across the
aortic valve. A 0.0035′′ super-stiff guidewire was then positioned
across the aortic arch. A balloon valvuloplasty catheter, selected
according to the annulus diameter, was positioned under fluoroscopic
and transoesophageal echocardiographic guidance and balloon valvulo-
plasty was performed under a brief period of rapid ventricular pacing.
The introducer sheath (30 Fr over-tube) containing the dilator was
introduced over the guidewire and positioned across the aortic valve
using fluoroscopic guidance. After removal of the dilator, the over-
tube sheath was held in its position. At this point, the Engager delivery
system with the mounted Engager valve was inserted into the over-
tube via the cone-shaped entrance, the support arms were pressed
against the shaft of the delivery catheter, and thus crimped into the
over-tube. Commissural alignment was performed under fluoroscopic
control with the valve still in the over-tube (Figures 2 and 3). Once the
delivery system exited the over-tube, the Engager support arms were
exposed in the aortic root, expanded laterally, and were gently with-
drawn under fluoroscopic guidance until they engaged against the
floor of the aortic sinuses, thus providing tactile feedback to the oper-
ator. Correct subcoronary positioning was verified by aortic root
Figure 1 Self-expanding Medtronic Engager (originally Ventor
Embracer) first-generation aortic valve bioprosthesis used in
this first-in-man series.
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Figure 3 Alignment of prosthetic and native commissures using angiography and fluoroscopy. (A) The left anterior oblique (LAO) view can
visualize the right (R) and left (L) coronary cusp and the commissure in between (a right anterior oblique view visualizes the commissure
between right and non-coronary cusp); (B) the commissure between the right and left aortic cusp (CRL) is defined by the tip of the intercusp
triangle spared by the contrast medium (arrow) and establishes the delivery axis; (C) a commissural post is aligned with the delivery axis when
the operator can see en face through its window (circle); anterior position of the post is verified by confirming movement to the right of the
image upon clockwise rotation of the delivery catheter under fluoroscopy (manoeuvre not shown); (D) when prosthetic and native commis-
sures are aligned, the support arms are released directly above the sinuses and, when pulled back, engage against the sinuses; (E) aortic root
angiography verifies correct subcoronary position of the support arms before deployment.
Figure 2 Principle of anatomically correct rotational positioning. 1 and 2, the commissural posts of the crimped prosthesis are rotated until
aligned with the native commissures (see also Figure 3); 3, when prosthetic and native commissures are aligned, the support arms are released
directly above the sinuses; 4, the system is pulled back until the support arms engage against the sinuses; 5, unsheathing of the mainframe results
in self-expanding release of the device and deployment is completed; 6, deployed device in situ (aortography).
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angiography in left and right anterior oblique (RAO) projections
(Figure 3). If necessary, repositioning could be performed under fluoro-
scopic/angiographic guidance by rotating the valve and re-aligning the
commissural posts with the native commissures. The safety button of
the delivery system was unlocked and rotation of the knob on the deliv-
ery system in a clockwise direction allowed gradual self-expanding unco-
vering of the prosthesis from its downstream to its upstream end. This
manoeuvre was performed under a second period of rapid ventricular
pacing (unless poorly tolerated by patient) and under continuous pull
to maintain stable valve position during release. With the last turn of
the knob, the device was released. Valve position and function were
immediately assessed using angiographic and echocardiographic
imaging as well as by simultaneous recording of the left ventricular
and aortic pressure curves (Figure 4). The transapical delivery system,
including the guidewire, was removed and the apex was closed with
the purse-string sutures. Intercostal blockade was performed using a
local anaesthetic. The pericardium was partially closed over the apex
and a left lateral chest tube inserted. The intercostal incision was
closed in a standard fashion. Femoral sheaths were removed. Postopera-
tive device-specific medical therapy consisted of aspirin 100 mg daily
indefinitely and clopidogrel 75 mg daily for 3 months except in patients
older than 85 years.
Statistical analysis
Standard methods for descriptive statistics have been used with data
presented as the mean+ standard deviation, or as the percentage of
patient sample, as appropriate. Statistics were calculated using Micro-
soft Excel version 2003.
Results
Patient characteristics
The baseline characteristics of the 30 enrolled are summarized in
Table 1. Mean age was 83.4+ 3.8 years; 83% were female. The
majority of patients was in NYHA class III (77%) or IV (13%) and
close to two-thirds had at least moderately impaired renal func-
tion. Half the patient had coronary artery disease. Mean logistic
EuroSCORE was 23.4+ 11.9. Mean aortic annulus diameter as
assessed by transoesophageal echocardiography was 21.8+
1.4 mm. Peak and mean aortic valve pressure gradients were
85.5+ 21.7 mmHg and 52.1+ 14.1 mm Hg, respectively. Fifty-
seven per cent had aortic insufficiency grade 1 and 26% aortic
insufficiency grade 2 or more.
Procedural details
Procedural details are summarized in Table 2. Accurate valve place-
ment was achieved in 29/30 cases (97%) (Figure 5). Mean fluoroscopy
time was 7.5+2.6 min; 129+58 mL of contrast medium was used
per procedure. Skin-to-skin time was 74+26 min (excluding con-
versions to sternotomy). The invasively measured peak-to-peak gra-
dient after valve implantation was 13.3+9.3 mmHg; corresponding
to a Doppler mean pressure gradient of 12.6+5.9 mmHg (peak
instantaneous Doppler gradient 24.6+10.0 mmHg). Aortic regurgi-
tation due to paravalvular leak grade 1 or less was present in 80%,
grades I–II in 13%, and grade II in 3% of the patients. Aortic insuffi-
ciency greater than grade II was not observed.
Procedure-related complications
Three patients (10%) required permanent pacemaker implantation
for complete or higher-degree atrioventricular block, or bradyar-
rhythmia with episodes of asystole. Five patients required temporary
dialysis or continuous veno-venous haemo-filtration in the early
postoperative period; of those, four had a diagnosis of pre-existing
chronic renal failure. In four patients (13%), aortic dissection was
diagnosed during or after implantation. One patient with localized
dissection of the ascending aorta was treated conservatively. The
Figure 4 Simultaneous recordings of the pressure tracings in the aorta (pigtail catheter) and the left ventricle (using an introducer sheath)
after implantation of a Medtronic Engager aortic valve in a patient with atrial fibrillation
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patient is alive and well at 1-year follow-up with normal valve func-
tion and mild paravalvular leakage. One patient with uneventful
implantation showed a type A dissection on post-implant transoeso-
phageal echocardiographic assessment and immediately underwent
root replacement and complete arch replacement. In one patient,
initial positioning of the support frame showed that one arm was
deployed in the left ventricular outflow tract, i.e. below instead of
within the non-coronary sinus. The delivery catheter was advanced
to reposition the non-coronary support arm above the valve. Intra-
procedural angiography and transoesophageal echocardiography
revealed a type A dissection posteriorly above the non-coronary
sinus. The procedure was converted to replacement of the aortic
root and the ascending aorta. The location of the dissection was
confirmed to be located posteriorly above the non-coronary
sinus. The fourth patient, after an uneventful implant procedure,
experienced an episode of severe chest pain on the regular ward
on day six. Computed tomography of the chest revealed a type A
dissection starting at the sinotubular junction extending circumfer-
entially for approximately 2708, with the left posterior aspect
spared. The patient was re-operated a day later, and the ascending
aorta and part of the aortic arch were replaced. Retrospective
review of the intraoperative angiography after device positioning,
but before deployment (Figure 6), revealed that a local dissection
above the non-coronary sinus had already been present. In all con-
verted cases, the Engager valve, which was located in an anatomi-
cally correct position, was explanted. Two of the three patients
who underwent surgical repair for type A dissection were dis-
charged from the hospital alive.
In one patient, post-dilatation was performed because of an
increased gradient after deployment, resulting in an acceptable
result (peak and mean gradients: 22/10 mmHg, grade II AR). Ten
hours post procedure, the patient developed atrial fibrillation, pul-
monary oedema and low cardiac output. Transoesophageal echo-
cardiography suggested mitral regurgitation grade III and outflow
tract turbulence compatible with moderate aortic regurgitation.
Reoperation was performed for suspected dislodgement of the
valve into the left ventricular outflow tract causing mitral valve
interference. At surgical inspection, the valve was found stable in
the proper position without detectable paravalvular gaps/dehis-
cence, nor any structural damage or impairment of the mitral
valve. The Engager valve was explanted and a 21 mm Mitroflow
valve was implanted. Retrospective analysis of the transoesopha-
geal echocardiographic study supports the view that the mitral
regurgitation was secondary to systolic anterior motion of the
mitral valve, also causing dynamic subaortic obstruction. The
patient had an uneventful recovery.
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Table 1 Patient baseline characteristics
Characteristic No. of
patients
%
Age (83.4+3.8)
≥90 years 2 7
80–89 years 25 83
Logistic EuroSCORE (23.4+11.9)
Female sex 25 83
Body mass index (kg/m2; 27.2+5.0)
≥25 21 70
Body surface area (m2; 1.74+0.17)
≥1.8 11 37
New York Heart Association class
II 3 10
III 23 77
IV 4 13
Hypertension 28 93
Syncope/presyncope 10 33
Dizziness on exertion 9 30
Angina pectoris 12 40
Diabetes 14 47
Coronary artery disease 14 47
Chronic pulmonary disease 5 17
Estimated glomerular filtration rate ,60 mL/
min/1.73 m2
19 63
Previous stroke 3 10
Extracardiac arteriopathy 14 47
Previous cardiac surgery 1 3
Ejection fraction ,50% 9 30
Mitral regurgitation
III 0 0
IV 0 0
Aortic regurgitation
None 5 17
I 17 57
II 7 23
III 1 3
Pulmonary hypertension (systolic pressure
.60 mmHg)
1 3
Atrial fibrillation 8 27
Pre-existing pacemaker 2 7
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Procedure details
Characteristic
Aortic annulus diameter (mm) 21.8+1.4
Accurate device placement (patients) 29 (97%)
Skin-to-skin time (min)a 74+16
Valve implantation time (min)b 6.0+2.4
Contrast medium volume (mL) 130+58
Fluoroscopy time (min) 7.5+2.6
Post-implantation dilatation (patients) 4 (13%)
aSkin-to-skin time is exclusive of the four patients who were converted to open
surgery.
bValve implantation time is defined as the time from over-tube insertion to
completion of valve deployment.
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Clinical outcome
Six patients (20%) died within 30 days post-implantation; a seventh
patient (90 years old EuroSCORE 63%) died after a prolonged hos-
pital stay after 61 days due to mesenteric ischaemia and sepsis
(in-hospital mortality 23%). In one patient, one support arm was
placed in the left ventricular outflow tract rather than the sinus
resulting in aortic insufficiency grade II. Since the patient was
haemodynamically stable, no re-intervention was performed.
After initial extubation, the patient suffered from respiratory dys-
function and was re-intubated. Reoperation was again considered
but ultimately not performed since aortic insufficiency was only
moderate and the overall condition was judged unfavourable for
open surgery. The patient developed low cardiac output and
expired on the fifth postoperative day. In one patient, severe
bleeding resulted from injury of the apex and required sternotomy
and cardiopulmonary bypass support to repair the left ventricle.
After a second revision, the patient required high-dose catechol-
amine support, developed metabolic acidosis, and died on the
same day. One patient was found unresponsive and pulseless on
the regular ward on the sixth postoperative day after an initially
uneventful recovery. Cardiac resuscitation was successful (echo-
cardiography showed a normally functioning valve prosthesis and
pericardial tamponade was ruled out), but the patient died of
anoxic brain damage on the tenth postoperative day. One
patient with initially uneventful recovery developed renal failure
requiring re-intubation and subsequently died of multi-organ
failure secondary to intestinal malperfusion on the third postopera-
tive day. Another patient with a prolonged recovery acquired a
norovirus infection and developed severe diarrhea. Despite ade-
quate supportive therapy, the patient died on the 29th postopera-
tive day of multi-organ failure. One patient developed intractable
atrial fibrillation with rapid ventricular response in the context of
a thyrotoxic crisis and expired due to refractory circulatory
failure. In all but the first patient, proper valve position and function
were confirmed by echocardiography. Mean and median hospital
stay were 25.0+20.6 days and 18 days (interquartile range
13.75–27.25), respectively. Survival at 6 months was 56.7%.
Discussion
Transapical aortic valve implantation (TA-AVI) has evolved into a
routine procedure for high-risk patients with aortic valve stenosis
in many centres of expertise.7,9,10 Despite the lack of randomized
trials comparing TA-AVI with standard open surgical aortic valve
replacement, it is generally assumed that the transcatheter
approach may potentially provide benefit to higher risk patients.
This assumption is based on the notion that minimally invasive
transcatheter valve implantation—by avoiding cardiopulmonary
bypass, cardiac ischaemia, and sternotomy—may limit
procedure-related risks in elderly patient. While some excellent
Figure 5 Pre- and post-implant intraoperative rotational angiography (DynaCT, Siemens) demonstrates anatomical positioning of the valve.
Figure 6 Angiography before deployment (right anterior
oblique projection). A local dissection (extravasation) can be
identified in direct continuation of the exposed prosthetic com-
missural post of the crimped valve (arrow) above the non-
coronary sinus (right posterior) during implantation of the
Embracer valve.
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results have been published, others report new complications
associated with transcatheter valve implantation, including valve
dislocation,11,12 left main stem occlusion,13 impairment of mitral
valve function,14 rupture of the aortic annulus,15 ventricular
septal defect,16 and aortic dissection.17 Data from the SOURCE
registry have shown that vascular complications, the necessity for
conversion to sternotomy, and residual aortic regurgitation
greater than grade II all have a direct impact on procedure-related
outcomes and are independent predictors of increased 30-day
mortality.2,18
Here, we report the results of a feasibility study with the Med-
tronic Engager transapical self-expanding valve. The shaped valve
is equipped with sinus support arms that allow for anatomically
correct positioning and deployment in a self-guided procedure,
and for axial fixation. This design prevents the native leaflets
from being pushed against the coronary arteries as they are
held against the main frame to provide additional sealing and mini-
mize paravalvular leakage. Commissural posts and leaflet design
create a mildly diverging outlet for optimal haemodynamic per-
formance by avoiding flow separation and enhancing pressure
recovery. The flared subvalvular inlet with barbs anchors the
prosthesis at the upstream side of the aortic annulus to prevent
device migration, provides a smooth entrance of flow into the
prosthesis, and seals the outflow tract to limit paraprosthetic
regurgitation.
While implantation of the valve was uneventful in the vast
majority of cases and accurate placement of the valve with all
support arms seated in the sinuses could be confirmed in all but
one patient, a number of complications were encountered and
need to be addressed. Of concern was the high rate of aortic dis-
sections observed in this study. Careful review of the imaging data
from procedures that resulted in dissections, revealed as the most
likely common mechanism an interaction between an exposed
prosthetic commissural post of the crimped bioprosthesis and
the posterior aspect of the aorta, above the non-coronary cusp,
as the delivery system was advanced into the ascending aorta
(Figure 6). The straight and rigid delivery system was unable to
conform to the angle between the left ventricle and the ascending
aorta. Therefore, the vector of advancement into the ascending
aorta had not only the intended superior component, but also
an undesired posterior component (towards the aortic wall).
This ventriculo-aortic angle can only be appreciated in the RAO,
but not the left anterior oblique view, since the latter looks at
this angulation en face (Figure 7). Elevation of the left ventricle
by stay sutures to enhance exposure, as customary in TA-AVI,
may further increase the ventriculo-aortic angle, and thus increase
the risk of aortic injury, particularly in the presence of small aortic
roots. As shown in Figure 8, the interaction between the straight
delivery system and the angulated anatomy was also the source
of potential misplacement of a support arm below the non-
coronary sinus that was observed in one case. It was therefore
concluded that a straight and rigid delivery system should be aban-
doned in favour of a delivery system with the following key attri-
butes: (i) flexible shaft for over-the-wire tracking, thus
conforming to the ventriculo-aortic angle and allowing co-axial
alignment with the ascending aorta; (ii) protective cover over the
prosthetic commissural posts until the valve’s final position prior
to the deployment of the main frame is confirmed. Based on
these learnings, such a system has been recently developed
(Figure 9) and is currently undergoing final testing. In addition,
several design modifications have been implemented in the valve
prosthesis itself: (i) increase in the space between support arms
and main frame to accommodate bulkier calcified leaflets and com-
missures; (ii) increase in radial strength at the waist (native annulus)
level to avoid the potential need for post-dilatation; (iii) reduction
in the length of the support arms to improve prosthesis confor-
mance to the native root anatomy.
Malpositioning (but without device embolization) was found in
3% (one case) which is in line with the data from other trials
using different implants.12,19 Importantly, the procedure has now
been modified to include confirmation of support arm position
in two planes, so that proper placement of all three support
arms can be ascertained prior to main frame deployment. In this
series, we did not observe coronary occlusion, which may
Figure 7 CT example showing that the ventriculo-aortic angle will be apparent in the RAO, but not the left anterior oblique equivalent of the
corresponding angiographic projections.
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Figure 8 Angiography before deployment (right anterior oblique view). Left: one support arm misplaced below the non-coronary sinus.
Right: lowering the shaft of delivery catheter to attenuate the angle resulted in successful capture of the non-coronary sinus. All support
arms are now above the valve and each is within an aortic sinus. The valve was successfully deployed.
Figure 9 Delivery system redesigned as a direct consequence of the FIM learnings. Left, single-piece apical introducer sheath containing flex-
ible delivery catheter with valve loaded and covered; right, delivery catheter after advancement and exposure of the support arms, with the
valve main frame and commissural posts still fully covered.
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potentially occur due to ostial obstruction by a displaced native
leaflet, inappropriately high positioning of a sealing cuff, the sup-
porting stent posts of an implanted valve, thrombo-embolic com-
plications, or dissection of the aortic annulus.10
The 20% 30-day and 23% in-hospital mortality in this
first-in-man series needs to be evaluated in the context of the
early transapical valve experiences with other implants. In the US
feasibility trial for the Sapien valve, a 17.5% 30-day and 22.5% in-
hospital mortality were reported.20 In the Partner EU trial, a multi-
centre trial that included 69 patients receiving an Edwards Sapien
valve, a similar mortality of 18.8% was reported. More recent
large single-centre studies and registry data show mortality rates
in the range of 8–17%2,21 and similar or better results than in
risk-adjusted groups of patients undergoing conventional surgery.22
Besides major cardiac and non-cardiac complications, the fre-
quent occurrence of paravalvular leakage and atrioventricular
block are of concern in transcatheter valve implantations. Paravalv-
ular leak resulting in aortic insufficiency of grade II or more is
reported at an incidence of up to 50%,11,12 may lead to elevated
left ventricular filling pressures, left ventricular dysfunction, haemo-
lysis, and promote endocarditis. Consequently, paravalvular leaks
should not simply be viewed as acceptable unavoidable collateral
damage.23 The rate of paravalvular leakage with the Engager
valve was within the range of the more favourable reported
implant series, with a low incidence of aortic insufficiency
grade II. The His bundle and its left bundle branch pass adjacent
to the non-coronary cusp of the aortic valve within the central
fibrous body. Local compression of the His bundle by the expand-
ing frame, especially in the setting of a thickened non-coronary
cusp, may therefore lead to atrioventricular block requiring
permanent pacemaker implantation and has a reported incidence
of 10–30% in patients undergoing transcatheter aortic valve
implantation.24 For the Engager valve, we observed a 10% inci-
dence of atrioventricular blocks requiring pacemaker implantation,
which is in line with previous reports.
While some of the reported complications are inherent to the
procedure and will not be preventable, others may be reduced
by careful patient selection and improved procedure planning.
This would include a better understanding of the behaviour of
the native valve during implantation and the interaction of the
implant and the native leaflets. Even the normal aortic valve
complex has significant regional asymmetry and anisotropy.25
The presence of asymmetric calcification patterns, variations in
aortic root geometry and in mechanical properties of the aorta,
the valve and the aortic annulus all may further impact the final
position of the valve and determine potential collateral damage
such as leaks and atrioventricular block. The valve selection
process may be further optimized based on individual anatomic cri-
teria that may favour one implant over the other for different path-
ologies. Models that have been developed so far allow to account
for native aortic root and device geometry (Figure 10).26 Given the
different behaviour of device materials (deformable Nitinol frames
conforming to the local anatomy vs. stainless steel remodelling the
implantation site27,28), modelling of their mechanical properties (in
addition to that of the pathology) would also be important to
achieve the important goal of knowledge-based valve selection.
This is of increasing interest as a variety of valve designs and
sizes is currently entering clinical trials. Enhanced imaging and mod-
elling, as well as augmented reality testing will most likely help to
select the best possible implant based on individual anatomic and
Figure 10 Preoperative planning using virtual implants in 3D reconstruction of the aortic root derived from intraoperative Dyna-CT data
demonstrating perfect anatomical alignment.
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morphologic data and facilitate the process of implantation in the
near future.29
Conclusion
This series has demonstrated the feasibility of implanting a novel
self-expanding transapical aortic valve prosthesis predictably into
an anatomically correct position within relatively short fluoroscopy
times. However, important complications have been observed,
which elicited a thorough review of procedure, delivery system,
and prosthesis. As a result of this process, the delivery system
has been completely redesigned, the valve prosthesis underwent
minor modifications, and both will be tested in upcoming clinical
studies with the goal of establishing safety and performance.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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